Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q3 2022
Institutional positions in Damora Therapeutics, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 26
- +3 vs. Q2 2022
- Shares held
- 9.16M
- +60.2K (+0.7%) vs. Q2 2022
- Total value
- $17.3M
- +$1.57M (+10.0%) vs. Q2 2022
- New holders
- 4
- 7 more added
- Sold out
- 1
- 4 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DMRA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 104 | $1.67B |
| Q1 2026 | 65 | $1.45B |
| Q4 2025 | 18 | $65.5M |
| Q3 2025 | 12 | $633.3K |
| Q2 2025 | 9 | $451.5K |
| Q1 2025 | 11 | $442.4K |
| Q4 2024 | 10 | $660.7K |
| Q3 2024 | 10 | $1.56M |
| Q2 2024 | 22 | $1.91M |
| Q1 2024 | 26 | $3.09M |
| Q4 2023 | 22 | $2.77M |
| Q3 2023 | 22 | $3.92M |
| Q2 2023 | 27 | $25.7M |
| Q1 2023 | 26 | $17.8M |
| Q4 2022 | 22 | $10.2M |
| Q3 2022 | 26 | $17.3M |
| Q2 2022 | 23 | $15.7M |
| Q1 2022 | 25 | $21.0M |
| Q4 2021 | 26 | $30.5M |
| Q3 2021 | 25 | $37.2M |
| Q2 2021 | 27 | $57.4M |
| Q1 2021 | 19 | $82.9M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Damora Therapeutics, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 4,090,937 | $7.73M | 0.15% | 00.0% | Unchanged |
| Novo Holdings A/S | 2,497,791 | $4.72M | 0.23% | 00.0% | Unchanged |
| Cormorant Asset Management, LP | 1,020,238 | $1.93M | 0.14% | 00.0% | Unchanged |
| MAI Capital Management | 338,915 | $641.0K | 0.01% | +18,055+5.6% | Added |
| Laurion Capital Management LP | 190,652 | $360.0K | 0.01% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 179,300 | $339.0K | 0.00% | −67,411−27.3% | Reduced |
| Bridgeway Capital Management, LLC | 173,100 | $327.0K | 0.01% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 106,136 | $200.0K | 0.00% | 00.0% | Unchanged |
| Two Sigma Advisers, LP | 92,000 | $174.0K | 0.00% | −12,900−12.3% | Reduced |
| Marquette Asset Management, LLC | 60,244 | $114.0K | 0.04% | 00.0% | Unchanged |
| Federated Hermes, Inc. | 60,000 | $113.0K | 0.00% | +20,000+50.0% | Added |
| Susquehanna International Group, LLP | 52,722 | $99.0K | 0.00% | +52,722 | New |
| Bank of America Corp | 46,838 | $89.0K | 0.00% | +9,826+26.5% | Added |
| Two Sigma Investments, LP | 46,544 | $88.0K | 0.00% | −16,751−26.5% | Reduced |
| State Street Corp | 44,906 | $85.0K | 0.00% | 00.0% | Unchanged |
| FNY Investment Advisers, LLC | 42,000 | $79.0K | 0.05% | +42,000 | New |
| Vanguard Group Inc | 34,219 | $65.0K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 20,551 | $39.0K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 18,795 | $36.0K | 0.00% | −11,562−38.1% | Reduced |
| BlackRock Inc. | 16,661 | $31.0K | 0.00% | +2,497+17.6% | Added |
| Commonwealth Equity Services, LLC | 10,179 | $19.0K | 0.00% | +10,179 | New |
| Simplex Trading, LLC | 9,608 | $18.0K | 0.00% | +9,123+1,881.0% | Added |
| UBS Group AG | 4,097 | $8.00K | 0.00% | +4,097 | New |
| Tower Research Capital LLC (TRC) | 3,015 | $6.00K | 0.00% | +423+16.3% | Added |
| Wells Fargo & Company | 2,994 | $5.00K | 0.00% | +8+0.3% | Added |
| JPMorgan Chase & Co | 854 | $2.00K | 0.00% | 00.0% | Unchanged |
| Curi Capital | 0 | $0 | 0.00% | −76−100.0% | Sold out |